Cardiovascular disease (CVD), including ischaemic heart disease (IHD) and heart failure (HF), and chronic obstructive pulmonary disease (COPD) are often concomitant because they share both risk factors (smoke) and pathological pathways (systemic inflammation). Cardiovascular disease and COPD association is increasing overtime. Several registries clearly showed a negative impact on the clinical outcome of the concomitant presence of CVD and COPD. Patients with CVD and COPD present an increased risk for myocardial infarction, HF, and hospital admission for acute exacerbation of COPD, with a negative impact on prognosis. To reduce the effect of this negative association, it is of paramount importance the pharmacological treatment with both cardiovascular and respiratory drugs, according to current guidelines. Nevertheless, several registries and studies showed that evidence-based drugs (both cardiovascular and respiratory) are often under administered in this subset of patients. In this overview, we summarize the available data regarding the use of cardiovascular drugs (antiplatelet agents, angiotensin converting enzyme inhibitors, b-blockers, and statins) in COPD patients, with or without concomitant IHD. Furthermore, we report advantages and disadvantages of respiratory drugs (b2 agonists, anti-cholinergics, and corticosteroids) administration in COPD patients with CVD.
Introduction
Cardiovascular disease (CVD), including ischaemic heart disease (IHD) and heart failure (HF), is still the first cause of mortality and morbidity in western countries. 1 Chronic obstructive pulmonary disease (COPD) will soon become the third most common cause of death. 2 Since CVD and COPD share major risk factors (e.g. cigarette smoking and systemic inflammation), they are frequently associated. 2 The concomitant presence of CVD and COPD negatively impacts on long-term prognosis. 3 Cardiovascular disease is the first cause of death in COPD patients 2 and, after acute exacerbation (AE) of COPD, we observed a significant increase in the risk of cardiac death and myocardial infarction (MI). 4 Similarly, patients admitted to hospital for MI and/or receiving coronary revascularization (percutaneous or surgical) with concomitant COPD showed a decreased short-and long-term survival. 5 -7 The aim of this overview is to summarize current data regarding cardiovascular drugs [antiplatelet, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), b-blocker (BB), and statin] in COPD patients with or without CVD, and respiratory drugs (b2 agonist, anti-cholinergic, and corticosteroid) in CVD -COPD patients.
Cardiovascular drugs in chronic obstructive pulmonary disease patients with or without concomitant cardiovascular disease Antiplatelet agents, ACE inhibitors or ARB, BB, and statins are the most commonly prescribed drugs in patients with CVD. 1 
Antiplatelet agents and chronic obstructive pulmonary disease
During AE of COPD, the platelet count increased significantly. 8 Thrombocytosis during AECOPD is associated with increased in-hospital and 1-year mortality (OR 2.37; 95% CI 1.29-4.34; and 1.53; 95% CI 1.03 -2.29, respectively). 9 We demonstrated that COPD patients treated with PCI have higher platelet reactivity (PR) when compared with patients without COPD. 10 The limited administration of ticagrelor may be partially explained by the fact that dyspnoea is one of the most commonly reported adverse events with ticagrelor. 16 Dyspnoea may occur up to the 20% of patients receiving ticagrelor (data from RCT). 16 Two RCTs evaluated the effect of ticagrelor on respiratory function including healthy subject and patients with asthma or COPD. 17 Ticagrelor did not alter pulmonary function at rest and during exercise. 17 Although these studies showed no interference by ticagrelor, physicians should be aware of this potential side effect that can affect up to one of five patients.
In conclusion, there is no evidence for using antiplatelet agents any differently among COPD patients than in non-COPD patients. COPD, chronic obstructive pulmonary disease; ACE I, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; AECOPD, acute exacerbation of COPD; LABA, long-acting b2 agonists; ICS, inhaled corticosteroids; Ach, inhaled anti-cholinergics; Y, yes; OR, odds ratio; CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; CR, coronary revascularization; HR, hazard risk; N, no; NS, not specified; PH, pulmonary hypertension; mPAP, mean pulmonary artery pressure; RCT, randomized clinical trial.
Angiotensin converting enzyme inhibitors or angiotensin receptor blocker and chronic obstructive pulmonary disease
Angiotensin II is a powerful vasoconstrictor, inflammatory modulator, and cellular growth factor. 18 Angiotensin II contributes to the inflammatory response that characterizes COPD. 18 Recently, Petersen et al.
showed that ACE inhibitor administration was related to lower FEV 1 decline in smokers. 19 These findings suggest a possible role for ACE inhibitors in modulating smoking effects on lung. 19 Angiotensin converting enzyme inhibitor or ARB administration in COPD patients has been suggested to manage pulmonary hypertension (PH) and to reduce all-cause mortality (Table 1) . Notably, studies evaluating their effect on PH are mainly small RCT, whereas those on hard clinical endpoints are post hoc analyses of observational and retrospective registries ( Table 1) . No RCT are available assessing if ACE inhibitor or ARB reduce mortality or AECOPD in COPD patients (Table 1 ).
In conclusion, available data are not sufficient to consider ACE inhibitor or ARB mandatory in COPD patients. They should be prescribed according concomitant disease (e.g. MI) and risk factors (e.g. arterial hypertension).
b-Blockers and chronic obstructive pulmonary disease b-Blockers are considered selective or not according the ability to block only b1 adrenergic receptors or both b1 and b2 adrenergic receptors. 26 Despite the positive effect of BB in COPD patients with IHD is well established, data on their utilization in daily clinical practice are not encouraging. Quint et al. reported that ,40% of eligible patients with MI and concomitant COPD received BB. 27 Comparably, in patients with HF, the presence of COPD represents the prevalent reason for BB avoidance. 28 Fisher et al. confirmed that, at the time of hospital discharge, COPD patients were less likely treated with evidence-based HF medications, including BB. 29 Cardioselective BB produced no change in FEV 1 or respiratory symptoms, as well as they did not affect the FEV 1 treatment response to longacting b2 agonists (LABA). 30 The use of cardioselective BB in COPD patients has to be encouraged also considering data on mortality. A meta-analysis including studies until 2011 showed a pooled relative risk reduction in mortality for COPD patients receiving BB (RR 0.69, 95% CI 0.62-0.78). 31 We reported in Table 2 all studies published subsequently. We did not have RCT evaluating the relationship between BB, COPD, and mortality.
In conclusion, BB administration in COPD patients is safe. Cardioselective BB, if indicated, should be administered in COPD patients, independently to pulmonary comorbidity. Although RCT are missing, all available studies suggest a mortality reduction in COPD patients assuming BB. proteins. 35, 36 Simvastatin reverses pulmonary vascular effects of cigarette smoke, including PH and emphysema. 37 Accordingly, several authors evaluated the potential role of statin administration in COPD patients to reduce both all-cause mortality and AECOPD. The majority of data are derived from registries and retrospective studies (Table 3) . Recently, a worthy RCT has been conducted. 38 The effect of simvastatin 40 mg on occurrence of AECOPD in patients with moderate-to-severe COPD has been evaluated in a prospective RCT. 38 The trial did not reached the primary endpoint, failing to demonstrate a change in the incidence of AECOPD in patients treated with simvastatin when compared with placebo. 38 No effect on hard cardiac endpoints was reported. 38 In conclusion, the potential benefit of statins in COPD patients has not been demonstrated. If indicated, statins must be administered to COPD patients, but there is no particular reason to start statins in COPD patients who do not otherwise have an indication.
Statins and chronic obstructive pulmonary disease

Oral anti-coagulants and chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease emerged as significant predictor of atrial fibrillation/atrial flutter (23 vs. 11%, P , 0.01) after adjustment for all confounding factors. 41 Warfarin is the most commonly prescribed oral anti-coagulant in general population. Retrospective studies reported that anti-coagulation treatment is inadequate in patients with atrial fibrillation and COPD. 41, 42 This may be explained by the higher occurrence of coexisting morbidities and by the higher risk of bleeding complications in COPD patients. 5, 43, 44 Nowadays, dabigatran, rivaroxaban, and apixan are available in the market. 45 They significantly reduced bleeding complications. 45 Nevertheless, no studies evaluated if this reduction is confirmed or different in COPD patients. Interestingly, in a substudy of the ROCKET-AF trial, COPD emerged as independent predictor of major bleeding risk. COPD, chronic obstructive pulmonary disease; LABA, long-acting b2 agonists; ICS, inhaled corticosteroids; ACh, inhaled anti-cholinergic; AECOPD, acute exacerbation of COPD; HR, hazard ratio; CI, confidence interval; CV, cardiovascular; GOLD, global initiative for chronic obstructive lung disease; ICD, international classification of disease; CRP, C-reactive protein; RR, relative risk.
In conclusion, although COPD patients are at higher risk of bleeding complications, oral anti-coagulants should not be denied if clinically indicated.
Respiratory drugs in patients with concomitant chronic obstructive pulmonary disease and ischaemic heart disease Treatment of COPD is based on long-acting inhaled bronchodilators (anti-cholinergics or LABA), inhaled corticosteroids (ICS) or a combination of these agents.
Acetylcholine antagonists
Ipratropium, oxitropium, and tiotropium are the most common anticholinergic drugs. 2 Patients treated with tiotropium are at higher risk of tachy-arrhythmias (RR 3.70, 95% CI 0.79 -17.4) and atrial tachycardias (RR 7.39, 95% CI 0.92-59.1). 47 The cardiovascular effects of inhaled anti-cholinergics have been evaluated in several studies (both RCT and registries). Some registries and post hoc analyses suggested a higher risk of cardiac adverse events in COPD patients receiving anti-cholinergics. In view of these concerns, systematic reviews and meta-analyses have been performed and we reported their results in Table 4 . Two main RCT investigated this topic. In the UPLIFT trial, tiotropium administration was associated with reduced 4-years cardiac mortality (HR 0.86, 95% CI 0.75-0.99). 48 To explain the differences, a relationship between formulation (dry-powder vs. aqueous solution), dose (18 vs. 5 mg), and the outcome has been suggested. Accordingly, the TIOSPIR trial has been planned. This was a large-scale (n ¼ 17183 patients), randomized, prospective evaluation of the safety and efficacy of tiotropium Respimat, when compared with tiotropium HandiHaler. 49 No difference in mortality, exacerbations, causes of death and major cardiovascular adverse events has been observed. 49 In conclusion, the administration of inhaled anti-cholinergics is safe and effective in COPD patients, also with concomitant CVD. In RCT, no effect on MI In RCT, no effect on CV death In RCT, no effect on mortality In COS, reduction of CV death (RR 0.79, 95%CI 0.72-0.86) In COS, no effect on mortality Singh et al. 57 
6522
Parallel 
Long-acting b2 agonists
The study of the relationship between LABA and cardiac adverse events in patients with concomitant COPD and CVD showed conflicting results. All data derived from registries. No RCT are available. Meta-analyses trying to assess the relationship between LABA and cardiac adverse events are reported in Table 4 . A post hoc analysis of the TORCH study merits a special consideration. 59 In this analysis, it was reported the relationship between salmeterol, fluticasone (in combination or alone) vs. placebo, and the incidence of CV adverse events. The analysis found that salmeterol alone or in combination with fluticasone did not increase the risk of events (HR 0.89, 95% CI 0.72-1.10). 59 In conclusion, LABA administration is safe. It showed only minor cardiac side effects and did not influence long-term mortality.
Inhaled corticosteroids
Inhaled corticosteroids are frequently prescribed to control progression and symptoms of COPD.
2 Even ICS cause a slight increase in gastrointestinal bleedings (HR 1.26, 95% CI 1.02-1.56). 60 Of note, the adequate use of spacer device reduced significantly these complications (0.26, 95% CI 0.2 -0.34). 60 To evaluate the safety and effectiveness of ICS in COPD patients, several RCT have been performed. Some studies have yielded conflicting results regarding survival and risk of MI. Meta-analysis clarifying this issue are reported in Table 4 .
In conclusion, no evidences support a negative relationship between ICS and mortality or cardiac adverse events in COPD patients with or without concomitant CVD.
Conclusions and future perspectives
Available studies strongly suggest that evidence-based treatment should not be modified in patients with concomitant presence of COPD and CVD. In daily clinical practice, it is mandatory to obtain the optimal titration of both cardiovascular and respiratory drugs. Available data strongly suggested that patients with concomitant COPD and CVD are at higher risk of death and adverse events. This is confirmed in several registries and trials. The early identification of the comorbidity and a prompt treatment of each singular disease may significantly improve the quality of life and the prognosis of these patients. Obviously, we did not have RCT on these topics and the majority of evidences are extrapolated from registries, observational studies or post hoc analysis from trials. Nevertheless, all findings are consistent and, awaiting further data from specific RCT, any effort should be considered to identify these patients and to optimize their pharmacological treatment.
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